Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa.
BACKGROUND: Lamivudine (3TC) is a potent inhibitor of both Hepatitis B virus (HBV) and Human Immunodeficiency Virus (HIV) replication and is part of first-line highly active antiretroviral therapy (HAART) in the Gambia. Unfortunately, the effectiveness of 3TC against HBV is limited by the emergence...
Κύριοι συγγραφείς: | Stewart, B, Jobarteh, M, Sarge-Njie, R, Alabi, A, de Silva, T, Peterson, K, Peterson, I, Whittle, H, Rowland-Jones, S, Jaye, A, Cotten, M, Mendy, M |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
BioMed Central
2011
|
Θέματα: |
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Emergence of HBV resistance to lamivudine (3TC) in HIV/HBV co-infected patients in The Gambia, West Africa
ανά: Stewart Balint, κ.ά.
Έκδοση: (2011-12-01) -
Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians.
ανά: Jobarteh, M, κ.ά.
Έκδοση: (2010) -
Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.
ανά: Jallow, S, κ.ά.
Έκδοση: (2009) -
Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.
ανά: Lijun Gu, κ.ά.
Έκδοση: (2015-01-01) -
Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians
ανά: Hall Andrew, κ.ά.
Έκδοση: (2010-09-01)